F0681
Factor V human
aqueous glycerol solution, ≥25 units/mg protein
Synonym(s):
Labile factor, Proaccelerin
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Recommended Products
General description
Factor V is a single chain glycoprotein involved in the blood coagulation cascade. It is the procofactor of Va which accelerates the conversion of prothrombin to thrombin.
Application
Factor V is a key component in blood coagulation systems, where deficiencies can inhibit thrombin generation and affect hemostasis. It has been used in studies of Coagulopathic bleeding which occurs following injury and is a leading cause of in hospital deaths.
Linkage
View this factors role in the Coagulation Cascade.
Unit Definition
One unit is equivalent to the Factor V activity in 1.0 mL of normal human plasma at pH 7.4 at 37 °C.
Physical form
Aqueous solution containing 50% (v/v) glycerol
Disclaimer
RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.
Storage Class Code
10 - Combustible liquids
WGK
WGK 2
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Sandro B Rizoli et al.
The Journal of trauma, 71(5 Suppl 1), S427-S434 (2011-12-17)
Coagulopathic bleeding is a leading cause of in-hospital death after injury. A recently proposed transfusion strategy calls for early and aggressive frozen plasma transfusion to bleeding trauma patients, thus addressing trauma-associated coagulopathy (TAC) by transfusing clotting factors (CFs). This strategy
Early coagulopathy in trauma patients: An on-scene and hospital admission study.
Floccard B., et al.
Injury (2010)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service